Intersectin-2 (ITSN2) is a multidomain scaffolding protein belonging to the intersectin family, primarily involved in regulating endocytosis, intracellular trafficking, and signal transduction. It contains conserved Eps15 homology (EH) domains and Src homology 3 (SH3) domains, enabling interactions with various partners to coordinate membrane dynamics, cytoskeletal reorganization, and receptor signaling. ITSN2 is expressed in diverse tissues, with notable roles in neuronal development, synaptic vesicle recycling, and cellular proliferation. Dysregulation of ITSN2 has been implicated in neurological disorders, cancer progression, and cardiovascular diseases, highlighting its functional versatility.
ITSN2 antibodies are essential tools for detecting and analyzing the expression, localization, and molecular interactions of ITSN2 in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunofluorescence, immunohistochemistry, and co-immunoprecipitation to study ITSN2's involvement in cellular processes like clathrin-mediated endocytosis, Ras-MAPK signaling, and PI3K-Akt pathway modulation. Polyclonal antibodies offer broad epitope recognition, while monoclonal antibodies provide high specificity. Validation via knockout controls or siRNA knockdown is critical to ensure antibody reliability, particularly given ITSN2's structural similarity to ITSN1. its paralog. Research utilizing ITSN2 antibodies continues to uncover its dual roles as a tumor suppressor or promoter, depending on cellular context, making it a focal point in therapeutic target exploration.